Contemporary systemic therapy for male breast cancer

Clinical Breast Cancer

Volumn 14, Issue 1, 2014, Pages 31-39

  Bradley, Katherine L ^a   Tyldesley, Scott ^a   Speers, Caroline H ^a   Woods, Ryan ^a   Villa, Diego ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Adherence; Aromatase inhibitors; Tamoxifen; Toxicity; Trastuzumab

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; HORMONE; LETROZOLE; TAMOXIFEN; TESTOSTERONE; TRASTUZUMAB;

ACNE; ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ANKLE INJURY; ANOREXIA; ARTHROPATHY; ARTICLE; BLURRED VISION; BODY WEIGHT DISORDER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; CANCER SURVIVAL; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY CANCER; ERECTILE DYSFUNCTION; FATIGUE; FEMALE; HAND DISEASE; HOT FLUSH; HUMAN; INSOMNIA; LEG CRAMP; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MALE BREAST CANCER; MEDICATION COMPLIANCE; MENTAL INSTABILITY; MIDDLE AGED; MUSCULOSKELETAL PAIN; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SWEAT GLAND DISEASE; SYSTEMIC THERAPY; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR INVASION; UNSPECIFIED SIDE EFFECT; VERY ELDERLY;

ADHERENCE; AROMATASE INHIBITORS; TAMOXIFEN; TOXICITY; TRASTUZUMAB;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; AROMATASE INHIBITORS; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 84892799381     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2013.09.001     Document Type: Article

References (50)

1. K.J. Bloom, H. Govil, and P. Gattuso et al. Status of HER-2 in male and female breast carcinoma Am J Surg 182 2001 389 392
2. M. Chavez-Macgregor, C.A. Clarke, and D. Lichtensztajn et al. Male breast cancer according to tumor subtype and race: a population-based study Cancer 119 2013 1611 1617
3. S.H. Giordano, G.H. Perkins, and K. Broglio et al. Adjuvant systemic therapy for male breast carcinoma Cancer 104 2005 2359 2364
4. I. Johansson, C. Nilsson, and P. Berglund et al. High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer Breast Cancer Res Treat 129 2010 747 760
5. D. Muir, R. Kanthan, and S.C. Kanthan Male versus female breast cancers. A population-based comparative immunohistochemical analysis Arch Pathol Lab Med 127 2003 36 41
6. P.E. Goss, C. Reid, and M. Pintilie et al. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996 Cancer 85 1999 629 639
7. G. Ribeiro, and R. Swindell Adjuvant tamoxifen for male breast cancer (MBC) Br J Cancer 65 1992 252 254
8. G. Ribeiro, R. Swindell, and M. Harris et al. A review of the management of the male breast carcinoma based on analysis of 420 treated cases The Breast 5 1996 141 146
9. M. Colleoni, S. Gelber, and A. Goldhirsch et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93 J Clin Oncol 24 2006 1332 1341
10. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group Lancet 351 1998 1451 1467
11. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 2005 1687 1717
12. B. Fisher, J. Dignam, and J. Bryant et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors J Natl Cancer Inst 88 1996 1529 1542
13. B. Fisher, J. Dignam, and J. Bryant et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial J Natl Cancer Inst 93 2001 684 690
14. H.J. Stewart, A.P. Forrest, and D. Everington et al. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group Br J Cancer 74 1996 297 299
15. D.C. Tormey, R. Gray, and H.C. Falkson Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group J Natl Cancer Inst 88 1996 1828 1833
16. I.A. Jaiyesimi, A.U. Buzdar, and A.A. Sahin et al. Carcinoma of the male breast Ann Intern Med 117 1992 771 777
17. H. Kantarjian, H.Y. Yap, and G. Hortobagyi et al. Hormonal therapy for metastatic male breast cancer Arch Intern Med 143 1983 237 240
18. M. Lopez, L. Di Lauro, and B. Lazzaro et al. Hormonal treatment of disseminated male breast cancer Oncology 42 1985 345 349
19. G.G. Ribeiro Tamoxifen in the treatment of male breast carcinoma Clin Radiol 34 1983 625 628
20. T.F. Anelli, A. Anelli, and K.N. Tran et al. Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients Cancer 74 1994 74 77
21. H. Visram, F. Kanji, and S.F. Dent Endocrine therapy for male breast cancer: rates of toxicity and adherence Curr Oncol 17 2010 17 21
22. C. Longcope, T. Kato, and R. Horton Conversion of blood androgens to estrogens in normal adult men and women J Clin Invest 48 1969 2191 2201
23. P.C. MacDonald, J.D. Madden, and P.F. Brenner et al. Origin of estrogen in normal men and in women with testicular feminization J Clin Endocrinol Metab 49 1979 905 916
24. E. Arriola, E. Hui, and M. Dowsett et al. Aromatase inhibitors and male breast cancer Clin Transl Oncol 9 2007 192 194
25. J. Doyen, A. Italiano, and R. Largillier et al. Aromatase inhibition in male breast cancer patients: biological and clinical implications Ann Oncol 21 2010 1243 1245
26. S.H. Giordano, V. Valero, and A.U. Buzdar et al. Efficacy of anastrozole in male breast cancer Am J Clin Oncol 25 2002 235 237
27. H. Eggemann, A. Ignatov, and B.J. Smith et al. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients Breast Cancer Res Treat 137 2013 465 470
28. F. Zagouri, T.N. Sergentanis, and V. Koutoulidis et al. Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series Br J Cancer 108 2013 2259 2263
29. L. Harris, H. Fritsche, and R. Mennel et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer J Clin Oncol 25 2007 5287 5312
30. M.A. Cobleigh, C.L. Vogel, and D. Tripathy et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 1999 2639 2648
31. H. Joensuu, P.L. Kellokumpu-Lehtinen, and P. Bono et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer N Engl J Med 354 2006 809 820
32. J. Mackey, D. McLeod, and J. Ragaz et al. Adjuvant targeted therapy in early breast cancer Cancer 115 2009 1154 1168
33. M.J. Piccart-Gebhart, M. Procter, and B. Leyland-Jones et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 2005 1659 1672
34. E.H. Romond, E.A. Perez, and J. Bryant et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 2005 1673 1684
35. D.J. Slamon, B. Leyland-Jones, and S. Shak et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
36. I. Smith, M. Procter, and R.D. Gelber et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 369 2007 29 36
37. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group J Natl Cancer Inst 88 1996 1543 1549
38. C. McCowan, J. Shearer, and P.T. Donnan et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer Br J Cancer 99 2008 1763 1768
39. J.A. Dewar, H.J. Stewart, and T.M. MacDonald Tamoxifen compliance in a clinical trial The Breast 5 1996 152 153
40. B. Fisher, J.P. Costantino, and C.K. Redmond et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 J Natl Cancer Inst 86 1994 527 537
41. A.H. Partridge, P.S. Wang, and E.P. Winer et al. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer J Clin Oncol 21 2003 602 606
42. V. Murthy, G. Bharia, and R. Sarin Tamoxifen non-compliance: does it matter? Lancet Oncol 3 2002 654
43. T.I. Barron, R. Connolly, and K. Bennett et al. Early discontinuation of tamoxifen: a lesson for oncologists Cancer 109 2007 832 839
44. A.K. Fink, J. Gurwitz, and W. Rakowski et al. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer J Clin Oncol 22 2004 3309 3315
45. C. Owusu, D.S. Buist, and T.S. Field et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer J Clin Oncol 26 2008 549 555
46. L.C. Harlan, J.A. Zujewski, and M.T. Goodman et al. Breast cancer in men in the United States: a population-based study of diagnosis, treatment, and survival Cancer 116 2010 3558 3568
47. I.C. Nordman, and D.N. Dalley Breast cancer in men: should aromatase inhibitors become first-line hormonal treatment? Breast J 14 2008 562 569
48. C. Bighin, G. Lunardi, and L. Del Mastro et al. Estrone sulphate, FSH, and testosterone levels in two male breast cancer patients treated with aromatase inhibitors Oncologist 15 2010 1270 1272
49. N. Mauras, K.O. O'Brien, and K.O. Klein et al. Estrogen suppression in males: metabolic effects J Clin Endocrinol Metab 85 2000 2370 2377
50. L.A. Korde, J.A. Zujewski, and L. Kamin et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations J Clin Oncol 28 2010 2114 2122